Purpose: 25OHD levels in patients with Prader-Willi Syndrome (PWS), the most frequent cause of genetic obesity with a peculiar fat mass distribution, are still debated. Insulin resistance (IR), Body Mass Index-SDS (BMI-SDS), Growth Hormone Therapy (GHT), and puberty onset seem to interact with 25OHD levels. The objectives of the study are: (1) To analyze 25OHD levels in pediatric PWS patients in comparison with a control group (CNT) (2) To evaluate a possible correlation between BMI-SDS, HOMA-IR, puberty, GHT, and 25OHD levels. Methods: This is a retrospective case–control, multicenter study. Data were collected among 8 different Italian Hospitals (outpatient clinics), over a period of four years (2016–2020). We included 192 genetically confirmed PWS and 192 CNT patients, aged 3–18 years, matched 1:1 for age, gender, BMI-SDS, Tanner stage, sun exposure, and month of recruitment. Results: No statistically significant differences in 25OHD levels were observed between the PWS population and the CNT (PWS 24.0 ng/mL vs CNT 22.5 ng/mL, p > 0.05), OR = 0.89 (95% CI 0.58–1.35). We observed a slight, although non-significant, reduction in 25OHD levels comparing NW and OB populations. HOMA-IR, puberty onset, genotype and GHT (previous or ongoing) did not show statistically significant correlation with 25OHD levels. Conclusions: Our findings could be useful for clinicians to optimize the therapeutic management as well as to increase awareness of PWS.
Multicentric Italian case-control study on 25OH vitamin D levels in children and adolescents with Prader-Willi syndrome / Panfili, F M; Convertino, A; Grugni, G; Mazzitelli, L; Bocchini, S; Crinò, A; Campana, G; Cappa, M; Delvecchio, M; Faienza, M F; Licenziati, M R; Mariani, M; Osimani, S; Pajno, R; Patti, G; Rutigliano, I; Sacco, M; Scarano, E; Fintini, D. - In: JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION. - ISSN 1720-8386. - 46:7(2023), pp. 1397-1406. [10.1007/s40618-022-01990-5]
Multicentric Italian case-control study on 25OH vitamin D levels in children and adolescents with Prader-Willi syndrome
Panfili, F M;Cappa, M;Rutigliano, I;Fintini, D
2023
Abstract
Purpose: 25OHD levels in patients with Prader-Willi Syndrome (PWS), the most frequent cause of genetic obesity with a peculiar fat mass distribution, are still debated. Insulin resistance (IR), Body Mass Index-SDS (BMI-SDS), Growth Hormone Therapy (GHT), and puberty onset seem to interact with 25OHD levels. The objectives of the study are: (1) To analyze 25OHD levels in pediatric PWS patients in comparison with a control group (CNT) (2) To evaluate a possible correlation between BMI-SDS, HOMA-IR, puberty, GHT, and 25OHD levels. Methods: This is a retrospective case–control, multicenter study. Data were collected among 8 different Italian Hospitals (outpatient clinics), over a period of four years (2016–2020). We included 192 genetically confirmed PWS and 192 CNT patients, aged 3–18 years, matched 1:1 for age, gender, BMI-SDS, Tanner stage, sun exposure, and month of recruitment. Results: No statistically significant differences in 25OHD levels were observed between the PWS population and the CNT (PWS 24.0 ng/mL vs CNT 22.5 ng/mL, p > 0.05), OR = 0.89 (95% CI 0.58–1.35). We observed a slight, although non-significant, reduction in 25OHD levels comparing NW and OB populations. HOMA-IR, puberty onset, genotype and GHT (previous or ongoing) did not show statistically significant correlation with 25OHD levels. Conclusions: Our findings could be useful for clinicians to optimize the therapeutic management as well as to increase awareness of PWS.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.


